由扩张型心肌病引起的心衰患者三年期存活率和左卡尼汀补充 Three-year survival of patients with heart failure and L-carnitine admin

We examined the efficacy of long-term L-carnitine administration for the treatment of heart failure caused by dilated car-diomyopathy in adult patients. To accomplish this, we studied 80 patients with moderate to severe heart failure (New York Heart Association classification III to IV) caused by dilated cordiomyopathy. 7his article reports on the nearly 3 years of fol-low-up data on patient mortality. Primary results will be published in the future. After a period of stable cardiac function up to 3 months, patients were randomly assigned to receive either L-carnitine (2 g/d orally) or placebo. There were no statisti-cal differences between the 2 groups at baseline examination in clinical and hemodynamic parameters, such as ejection fraction, Weber classification, maximal time of cardiopulmonary exercise test, peak VOy consumption, arterial and pul-monary blood pressure, and cardiac output. After a mean of 33.7 1 1 1.8 months of follow-up (range 10 to 54 months),70 patients were in the study: 33 in the placebo group and 37 in the L-carnifine group. At the time of analysis, 63 patients were alive. There were 6 deaths in the placebo group and 1 death in the L-carnitine group. Survival analysis with the Kaplan-Meier method showed that patients' survival was statistically significant (P<.04) in favor of the L-carnitine group.L-cornitine appears to possess considerable potential for the long term treatment of patients with heart failure attributable to dilated cardiomyopathy. (Am Heart) 2000;139:S120-S123.)

详情请点击下载PDF文件。